Search for content, post, videos

FDA approves Calliditas’ TARPEYO

Renée Aguiar-Lucander Photo Jann Lipka

Calliditas Therapeutics has announced that the US Food and Drug Administration (FDA) has approved TARPEYO (budesonide) delayed release capsules to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥1.5g/g.

This indication is approved under accelerated approval. It has not been established whether TARPEYO slows kidney function decline in patients with IgAN. Continued approval may be contingent upon verification and description of clinical benefit in a confirmatory clinical trial.

A commercial-stage biopharmaceutical company

This approval marks the successful transition for Calliditas to a commercial-stage biopharmaceutical company, the company states.

“We are very excited to bring the first and only FDA-approved treatment to reduce proteinuria in IgAN to market,” says Renée Aguiar-Lucander, Chief Executive Officer of Calliditas. “TARPEYO represents an FDA approved product to help these patients who are at risk of rapid disease progression.”

Read more: Q&A: Renée Aguiar-Lucander, CEO, Calliditas Therapeutics


TARPEYO is approved under accelerated approval based on achieving its primary endpoint of reduction in proteinuria in Part A of the NeflgArd Phase 3 study, an ongoing, randomized, double-blind, placebo-controlled, multicenter study conducted to evaluate the efficacy and safety of TARPEYO 16 mg once daily vs placebo in adult patients with primary IgAN. The effect of TARPEYO was assessed in patients with biopsy-proven IgAN, eGFR ≥35 mL/min/1.73 m2, and proteinuria (defined as either ≥1 g/day or UPCR ≥0.8 g/g) who were on a stable dose of maximally-tolerated RAS inhibitor therapy.

Patients taking TARPEYO (n=97) showed a statistically significant 34% reduction in proteinuria from baseline vs 5% with RASi alone (n=102) at 9 months. The treatment effects for the primary endpoint of UPCR at 9 months were consistent across key subgroups, including key demographic and baseline disease characteristics.1

The most common adverse reactions (≥5%) in this study were hypertension, peripheral edema, muscle spasms, acne, dermatitis, weight increase, dyspnea, face edema, dyspepsia, fatigue, and hirsutism.  Please see additional Important Safety Information below.

Available in the U.S. early in the first quarter of 2022

“TARPEYO was developed to target a root cause of IgAN. The FDA’s approval of TARPEYO demonstrates our  unwavering dedication to patients suffering from IgAN. We would like to thank the patients, researchers and clinical staff who participated in the studies of TARPEYO,” says Richard Philipson, Calliditas Chief Medical Officer.

It is expected that TARPEYO will be available in the U.S. early in the first quarter of 2022.

Photo of Renée Aguiar-Lucander, CEO, Calliditas: Jann Lipka